BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Cord Blood Banking Opinions Issued by Medical Societies
Medical Opinions of Cord Blood Banking

Cord Blood Banking Opinions Issued by Medical Societies

May 21, 2016 By Cade Hildreth (CEO) Leave a Comment

When considering the value of cord blood banking, it is interesting to consider recommendations about cord blood banking issued by medical societies, associations, and ethics committees.

Discover class-defining bioproduction tools.

In most cases, medical societies have issued positive stances toward public cord blood banking, but have shown little support for the private sector. However, there are exceptions made for families that have a predisposition to a condition in which cord stem cells could be therapeutically applied.

Recommendations on Cord Blood Banking Issued by Medical Societies

The table below shows opinions issued by medical societies about cord blood banking. Interestingly, all of these recommendations are based on outdated transplant statistics, ranging from 2004 to 2009.

Rooster DevServices

As far as we are currently aware, no U.S. medical body has issued a renewed stance on cord blood banking over the past several years.

bitbio

(*Note: If you are a member of a medical society that has issued a more up-to-date stance, please comment below.)

This is somewhat surprising, because technology in the cord blood industry is rapidly advancing for processing technologies, storage techniques, transplant methodologies, ex vivo expansion technologies and more.  Furthermore, none of these medical societies have included a consideration of emerging therapies while establishing their positions and guidelines.

Pluristyx

The reason that emerging therapies are not considered in these recommendations is that they cannot easily be compared against current medical alternatives. Projected therapies that may one-day exist, including those that will arise within a timeline to allow currently stored cord blood samples to be utilized, are not considered because they are speculative.

TABLE. Cord Blood Banking Opinions Issued by Medical SocietiesMedical Society Opinions of Cord Blood Banking*Click on the table to enlarge.

iPSC-derived cardiomyocte therapy

Medical Societies Positive Toward Public Cord Blood Banking

As shown above, medical societies have issued largely positive stances toward public cord blood banking, and negative stances toward private cord blood banking, with exceptions made for families who have a history of disease that could be addressed through cord blood stem cell transplant.

However, these opinions are largely outdated and it would be optimal for new stances to be published based on newer technologies and applications.

Therefore, it is up to the individual consumer to learn about the advantages of cord blood transplant over other alternatives, such as bone marrow and peripheral blood. You are then positioned to weight the value of private cord blood storage against the cost involved.

For public cord blood banking, the costs are covered by the public bank, which makes it an intelligent choice for most (if not all) families who can access the service.

About Us

BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been featured on prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving industry leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in cord blood industry data.

To learn more about the cord blood banking industry, view the “Complete 2015-16 Global Cord Blood Banking Industry Report.”

 

Rate this post

Filed Under: Cord Blood, HSCs Tagged With: cord blood, hematopoietic stem cells, Ob/Gyn, private banking, public banking

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

Feature | Exosome Companies | Exosome Companies | Tiny Exosomes, Enormous Potential

List of Exosome Companies: Tiny Packages, Enormous Potential

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.